Pantoprazole (Iv) Sun

Pantoprazole, the active ingredient in Pantoprazole (Iv) Sun, is a proton pump inhibitor presented as a 40 mg/100 ml solution for intravenous use. It reduces gastric acid secretion and is used in the management of gastro‑oesophageal reflux disease and related conditions in adult patients.

GNH USA supplies Pantoprazole (Iv) Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Pantoprazole is a proton pump inhibitor that acts on the acid‑production pathway of the stomach. It is indicated for several gastrointestinal disorders where acid suppression is required. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with gastrin‑producing tumours.

Adverse reactions may occur with pantoprazole use. Monitoring and reporting are important, especially for unexpected events.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea: transient and often mild. - Abdominal pain: occasional discomfort. - Flatulence: mild bloating. - Constipation: occasional change in bowel habit.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): requires immediate medical attention. - Clostridioides difficile‑associated colitis: may present with severe diarrhea. - Acute interstitial nephritis: renal function monitoring recommended. - Hepatic dysfunction: elevated liver enzymes observed. - Low magnesium levels (hypomagnesemia): can cause muscle cramps or arrhythmia. - Bone fractures: long‑term use linked to increased fracture risk.

Pantoprazole should be used with consideration of patient‑specific factors and monitoring requirements. - Assess renal function: dose adjustment may be needed in severe impairment. - Evaluate hepatic function: use with caution in moderate to severe liver disease. - Review concomitant medications: potential for reduced efficacy of drugs requiring acidic pH for absorption. - Monitor electrolytes: prolonged therapy may affect magnesium and calcium levels. - Pregnancy and lactation: prescribe only if benefit outweighs risk. - Store at ambient temperature: keep in original packaging, protect from light and moisture.

Pantoprazole can affect the pharmacokinetics of several co‑administered medicines. Interaction management depends on clinical relevance.

Major Interactions (Avoid): - Ketoconazole or itraconazole: reduced antifungal absorption. - Atazanavir: markedly decreased antiviral exposure. - Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR. - Digoxin: slight increase in serum levels. - Methotrexate: reduced renal clearance at high doses. - Mycophenolate mofetil: increased exposure. - Iron supplements: decreased iron absorption.